Han‐Seung Park

Targeting CDK7 to overcome hypomethylating agent resistance in acute myeloid leukemia

Abstract Purpose Hypomethylating agents (HMAs), such as azacitidine and decitabine, are widely used in elderly or medically unfit patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). However, most patients eventually develop primary or acquired resistance...